Gemtesa FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 25, 2021.
FDA Approved: Yes (First approved December 23, 2020)
Brand name: Gemtesa
Generic name: vibegron
Dosage form: Tablets
Company: Urovant Sciences
Treatment for: Overactive Bladder
Gemtesa (vibegron) is a once-daily beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.
Development timeline for Gemtesa
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.